Taysha Gene Therapies Inc <TSHA.OQ> expected to post a loss of 8 cents a share - Earnings Preview
Taysha Gene Therapies Inc TSHA.OQ TSHA.O is expected to show a rise in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
The Dallas Texas-based company is expected to report a 44.3% increase in revenue to $1.605 million from $1.11 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Taysha Gene Therapies Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $8.00, about 64.9% above its last closing price of $2.81
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.09 | -0.09 | -0.08 | Beat | 13.6 |
Dec. 31 2025 | -0.08 | -0.08 | -0.07 | Beat | 15.7 |
Sep. 30 2024 | -0.10 | -0.09 | -0.10 | Missed | -8 |
Jun. 30 2024 | -0.16 | -0.16 | -0.09 | Beat | 45.3 |
Mar. 31 2024 | -0.12 | -0.11 | -0.10 | Beat | 8.6 |
Dec. 31 2023 | -0.11 | 0.92 | Beat | 936.4 | |
Sep. 30 2023 | -0.19 | -0.17 | -0.13 | Beat | 24.7 |
Jun. 30 2023 | -0.31 | -0.31 | -0.38 | Missed | -22.1 |
This summary was machine generated August 8 at 16:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
